GVS (GVS) Q3 2024 earnings summary

Executive summary

• Consolidated revenues for the first nine months of 2024 reached €321.7 million, up 3.7% at constant exchange rates year-over-year, with strong Q3 organic growth of 8.1% driven by Healthcare & Life Sciences and Health & Safety divisions, offsetting Energy & Mobility weakness.

• Adjusted EBITDA rose 13% to €78.1 million, with margin improving to 24.3% from 22.1% in 2023.

• Adjusted net income increased 20.5% to €33.9 million, with margin at 10.5%; net income attributable to shareholders was €19.5 million, up from €15.8 million.

• Leverage ratio improved to 2.30x from 2.65x at December 2023, with net financial debt at €238.9 million.

• Strong cash generation from operations supported deleveraging and investments.

Financial highlights

• Revenue: €321.7 million (+3.7% YoY at constant FX); Adjusted EBITDA: €78.1 million (+13% YoY); EBIT: €56.6 million (+15.5% YoY).

• Adjusted net income margin increased to 10.5% from 9.0% YoY; EPS: €0.11 (up from €0.09).

• Net financial debt: €238.9 million (down from €252.1 million at December 2023); net investments in tangible and intangible assets totaled €27.9 million.

• ROE: 7% (2023: 6%); ROI: 11% (2023: 9%); ROS: 17% (2023: 16%).

• Working capital absorption in Q3 linked to higher trade and tax receivables; cash and cash equivalents at period end were €76.2 million.

Outlook and guidance

• FY 2024 organic sales growth expected at 2-3% over FY 2023, with normalised EBITDA margin projected to increase by 180–220 basis points.

• Adjusted leverage ratio expected around 2x at year-end 2024.

• 2025 outlook remains cautious, with focus on executing the industrial plan and adapting to market/geopolitical conditions.

• Margin improvement in 2025 expected from internal efficiencies and cost reductions, even if top-line growth remains modest.